603127 Joinn Laboratories
- 19.60
- +0.45+2.35%
Joinn Laboratories News
Joinn Laboratories (603127.SH): Cumulative repurchase of 0.2806% A-share shares.
On November 1, Gelunhui reported that Joinn Laboratories (603127.SH) announced that as of October 31, 2024, the company has cumulatively repurchased 2,103,100 shares of A shares through centralized auction trading, accounting for 0.2806% of the total shares on the date of this announcement. The highest repurchase price was RMB 18.15 per share, and the lowest repurchase price was RMB 13.20 per share, with a total amount of RMB 33,195,984.40 (excluding transaction costs).
Joinn Laboratories' Q3 Profit Slides 58%
Zhaoyan Pharmaceutical: Zhaoyan New Pharmaceutical Report for the Third Quarter of 2024
Zhaoyan New Pharmaceutical Report for the Third Quarter of 2024
Joinn Laboratories (06127) plans to invest no more than 0.1 billion yuan in setting up the second phase fund of the service trade.
Joinn Laboratories (06127) announced that, in order to fulfill the policy mission of national funds, it will fully support the company's business development and provide...
Express News | Joinn Laboratories China - Qtrly Rev RMB485.8 Mln
Express News | Joinn Laboratories China - Qtrly Net Profit Attributable RMB99.4 Mln
JOINN: 2024 THIRD QUARTERLY REPORT
Joinn Laboratories (06127.HK) nominated Luo Xi as an executive director.
Joinn Laboratories (06127.HK) announced on October 30 that the board of directors recently received Dr. Yao Dalin's resignation letter. As a result, Dr. Yao resigned as an executive director and deputy general manager of the company due to work arrangements. The board of directors resolved to nominate Ms. Luo Xi as an executive director of the company. The appointment of Ms. Luo is subject to approval by the shareholders in the first extraordinary general meeting of the company in 2025 in the form of an ordinary resolution.
Express News | Joinn Laboratories China Co Ltd - Yao Dalin Resigned as Executive Director
Has Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
JOINN Laboratories Schedules Board Meeting to Review Q3 Results
Joinn Laboratories (06127.HK) plans to hold a board of directors meeting on October 30 to approve the third-quarter performance.
Oct. 18th, Geelongi News: Joinn Laboratories (06127.HK) announced that the board of directors hereby notifies that a board meeting will be held on October 30, 2024 (Wednesday) to consider and approve (including) the Group's third quarter performance for the nine months ending on September 30, 2024, and its release.
JOINN: DATE OF BOARD MEETING
Joinn Laboratories (06127.HK) received a shareholding of 0.0715 million shares from UBS Group AG.
According to the latest equity disclosure data from the Hong Kong Stock Exchange on October 17th, 2024, joinn laboratories (06127.HK) received UBS Group AG's on-exchange shareholding of 0.0715 million shares at an average price of 10.6032 Hong Kong dollars per share, involving approximately 0.7581 million Hong Kong dollars. After the shareholding, UBS Group AG's latest number of shares held is 5,995,399 shares, and the shareholding percentage has increased from 4.98% to 5.04%.
joinn laboratories (603127.SH): cumulatively repurchased 0.2806% of shares
On October 8, GeLongHui announced that, as of September 30, 2024, the company had cumulatively repurchased 2,103,100 A-shares through centralized bidding trade, accounting for 0.2806% of the total shares outstanding on the announcement date. The highest repurchase price was RMB 18.15 per share, the lowest repurchase price was RMB 13.20 per share, and the total amount used for the repurchase was RMB 33,195,984.40 (excluding transaction fees).
[Brokerage Focus] China Post Securities expects the pharmaceutical sector to continue to rise uniformly, suggesting prioritizing the layout of various segmented sectors and leading companies in the first and second tiers during the general rise phase.
Golden Herald Financial News | China Post Securities stated that since the end of September, the pharmaceutical sector has been boosted by the national comprehensive incremental policy, solidly promoting the economy towards a higher-quality structure under the heavy bullish push, leading to a rapid rebound of the index by about 29%, reversing the continuous decline of nearly 4 years. Looking at the current PE (TTM), A-share pharmaceuticals are at 32 times, and Hong Kong stocks at 23 times. The previous continuous decline has already deviated from the fundamentals. The bank believes that the increase in market risk appetite will accelerate the sector's valuation repair. As of H1 2024, the institutions hold a 7.3% stake in the CSI SWS Health Care Index sector, which, although slightly lower than the end of 2023, still remains at a historically high level, indicating a general positive sentiment among institutions.
Trending Industry Today: JOINN Leads Gains In CRO Stocks
Revenues Not Telling The Story For Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) After Shares Rise 28%
JOINN: 2024 Interim Report
Analysis
Price Target
No Data
No Data